IP Library Patent Application 13319724
Patent Application
App. No. 13/319,724

Method for Identifying Inhibitors Against Dengue Virus

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/319,724
Abstract

The present invention concerns a method for identifying inhibitors against dengue virus subtypes 1, 2, 3 or 4 and its use in a high throughput mode.

Claims (13)

1 . Method for identifying inhibitors against dengue viruses serotypes 1, 2, 3 or 4 by screening chemical compounds or chemical compound libraries comprising:

a) bringing about 1000 to 2000 Vero cells or Huh 7.5 cells into contact with a chemical compound,

b) adding dengue virus to said cells and chemical compound of step a),

c) incubating said cells, chemical compound and virus of step b) at 37° C. until viral cytopathic effect (CPE) in the virus control reaches about 100%,

d) adding luciferase enzyme and luciferase substrate to the cells, compound, virus,

e) measuring the luminescence and calculating the EC 50 value, wherein the EC 50 value correlates with the inhibitory activity of the compound against dengue virus.

2 . Method according to claim 1 wherein the dengue virus is Dengue Virus subtype 2 and the cells are about 1500 Vero cells.

3 . Method according to claim 1 wherein the dengue virus is Dengue Virus subtype 1, 3 or 4 and the cells are Huh 7.5 cells.

4 . Method according to claim 1 wherein the dengue virus has a multiplicity of infection (MOI) of 0.1, 0.5 or 1.0, preferably 0.1.

5 . Method according to claim 1 wherein the dengue virus has a multiplicity of infection (MOI) between 1.0 and 10.0.

6 . Method according to claim 1 wherein step c) is about 5 or 6 days.

7 . Method according to claim 1 wherein the luciferase substrate is D-Luciferin.

8 . Method according to claim 1 wherein the method is performed in a high throughput mode.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2014
From: GONG, EDWIN YUNHAO; IVENS, TANIA PAULINE EDUARD; LORY, PEDRO MIGUEL JALES; KRAUS, GUENTER
To: TIBOTEC BVBA
Reel/Frame 032514/0979 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2014
From: CLYNHENS, MARLEEN
To: VIRCO BVBA
Reel/Frame 032515/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2014
From: VIRCO BVBA
To: TIBOTEC PHARMACEUTICALS
Reel/Frame 032515/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2014
From: TIBOTEC BVBA
To: TIBOTEC PHARMACEUTICALS
Reel/Frame 032515/0093 →
CHANGE OF NAME Recorded Mar 25, 2014
From: TIBOTECH PHARMACEUTICALS
To: JANSSEN R&D IRELAND
Reel/Frame 032515/0150 →